Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar

By sjmartinez • July 5, 2022

Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Büdingen HC, Kou X, Weber K, Greenberg B. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022 Jul 5;66:104025. doi: 10.1016/j.msard.2022.104025. Epub ahead of print. PMID: 36007339.

All clinical trials, All demyelinating disease (CNS), Autoimmune diseases, Devic's syndrome, Neuromyelitis optica spectrum disorder, Patient safety,

Tags: Digestive Diseases, Publications

A Practical Approach to the Diagnosis and Management of Hepatic Encephalopathy

Reau N, Bernstein D, Kwo P, Loftus M, Moore A, Saab S. A Practical Approach to the Diagnosis and Management of Hepatic Encephalopathy. Am J[...]

The impact of frailty on liver transplant candidacy – A survey study on current clinical practices in the United States

Thuluvath AJ, Buckholz A, Patel A, Verna EC, Duarte-Rojo A. The impact of frailty on liver transplant candidacy - A survey study on current clinical[...]

Reply to Letter on “Sex-Specific Trends and Demographic vs Epidemiologic Drivers of Alcohol-Related Cirrhosis in the U.S., 2021-2040”

Danpanichkul P, Diaz LA, Arab JP, Singal AG, Yang JD. Reply to Letter on "Sex-Specific Trends and Demographic vs Epidemiologic Drivers of Alcohol-Related Cirrhosis in[...]